These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 14722288)
1. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. Chen YF; Lin CW; Tsao YP; Chen SL J Virol; 2004 Feb; 78(3):1333-43. PubMed ID: 14722288 [TBL] [Abstract][Full Text] [Related]
2. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264 [TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770 [TBL] [Abstract][Full Text] [Related]
4. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264 [TBL] [Abstract][Full Text] [Related]
5. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. Ossevoort MA; Feltkamp MC; van Veen KJ; Melief CJ; Kast WM J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):86-94. PubMed ID: 8574470 [TBL] [Abstract][Full Text] [Related]
7. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657 [TBL] [Abstract][Full Text] [Related]
8. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11. Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861 [TBL] [Abstract][Full Text] [Related]
9. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Kim TG; Kim CH; Won EH; Bae SM; Ahn WS; Park JB; Sin JI Immunology; 2004 May; 112(1):117-25. PubMed ID: 15096191 [TBL] [Abstract][Full Text] [Related]
10. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211 [TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo. Yang Y; Che Y; Zhao Y; Wang X Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. Weijzen S; Meredith SC; Velders MP; Elmishad AG; Schreiber H; Kast WM J Immunol; 2001 Jun; 166(12):7151-7. PubMed ID: 11390461 [TBL] [Abstract][Full Text] [Related]
14. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078 [TBL] [Abstract][Full Text] [Related]
15. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Sarkar AK; Tortolero-Luna G; Nehete PN; Arlinghaus RB; Mitchell MF; Sastry KJ Viral Immunol; 1995; 8(3):165-74. PubMed ID: 8833270 [TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
17. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
18. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358 [TBL] [Abstract][Full Text] [Related]
19. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice. Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808 [TBL] [Abstract][Full Text] [Related]
20. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]